Updates and controversies in the rapidly evolving field of lung cancer screening, early detection, and chemoprevention

Cancers

Volumn 6, Issue 2, 2014, Pages 1157-1179

  Kathuria, Hasmeena ^a   Gesthalter, Yaron ^a   Spira, Avrum ^a,b   Brody, Jerome S ^a   Steiling, Katrina ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Chemoprevention; Early detection; Lung cancer; Screening

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANETHOLE TRITHIONE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; ISOTRETINOIN; MAMMALIAN TARGET OF RAPAMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; SELENIUM;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; COMPUTER ASSISTED TOMOGRAPHY; DNA METHYLATION; EARLY DIAGNOSIS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SMOKING; SMOKING CESSATION; SPUTUM CYTODIAGNOSIS; SURVIVAL RATE; SURVIVAL TIME; THORAX RADIOGRAPHY;

EID: 84901236222     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6021157     Document Type: Review

References (120)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63, 11-30.
2. Yabroff, K.R.; Lamont, E.B.; Mariotto, A.; Warren, J.L.; Topor, M.; Meekins, A.; Brown, M.L. Cost of care for elderly cancer patients in the United States. J. Natl. Cancer Inst. 2008, 100, 630-641.
3. Howlader, N.; Noone, A.M.; Krapcho, M.; Garshell, J.; Neyman, N.; Altekruse, S.F.; Kosary, C.L.; Yu, M.; Ruhl, J.; Tatalovich, Z. et al. SEER cancer statistics review (CSR), 1975-2010. Available online: http://seer.cancer.gov/csr/1975_2010/sections.html (accessed on 11 December 2013).
4. Humphrey, L.L.; Deffebach, M.; Pappas, M.; Baumann, C.; Artis, K.; Mitchell, J.P.; Zakher, B.; Fu, R.; Slatore, C.G. Screening for lung cancer with low-dose computed tomography: A systematic review to update the US Preventive services task force recommendation. Ann. Intern. Med. 2013, 159, 411-420.
5. Wakelee, H.A.; Chang, E.T.; Gomez, S.L.; Keegan, T.H.; Feskanich, D.; Clarke, C.A.; Holmberg, L.; Yong, L.C.; Kolonel, L.N.; Gould, M.K. et al. Lung cancer incidence in never smokers. J. Clin. Oncol. 2007, 25, 472-478.
6. Thu, K.L.; Vucic, E.A.; Chari, R.; Zhang, W.; Lockwood, W.W.; English, J.C.; Fu, R.; Wang, P.; Feng, Z.; MacAulay, C.E. et al. Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability. PLoS One 2012, 7, e33003.
7. Bach, P.B.; Kattan, M.W.; Thornquist, M.D.; Kris, M.G.; Tate, R.C.; Barnett, M.J.; Hsieh, L.J.; Begg, C.B. Variations in lung cancer risk among smokers. J. Natl. Cancer Inst. 2003, 95, 470-478.
8. Cronin, K.A.; Gail, M.H.; Zou, Z.; Bach, P.B.; Virtamo, J.; Albanes, D. Validation of a model of lung cancer risk prediction among smokers. J. Natl. Cancer Inst. 2006, 98, 637-640.
9. Spitz, M.R.; Hong, W.K.; Amos, C.I.; Wu, X.; Schabath, M.B.; Dong, Q.; Shete, S.; Etzel, C.J. A risk model for prediction of lung cancer. J. Natl. Cancer Inst. 2007, 99, 715-726.
10. Cassidy, A.; Myles, J.P.; van Tongeren, M.; Page, R.D.; Liloglou, T.; Duffy, S.W.; Field, J.K. The LLP risk model: An individual risk prediction model for lung cancer. Br. J. Cancer 2008, 98, 270-276.
11. D'Amelio, A.M.; Cassidy, A.; Asomaning, K.; Raji, O.Y.; Duffy, S.W.; Field, J.K.; Spitz, M.R.; Christiani, D.; Etzel, C.J. Comparison of discriminatory power and accuracy of three lung cancer risk models. Cancer Prev. Res. (Phila) 2010, 3, Abstract A127.
12. Iyen-Omofoman, B.; Tata, L.J.; Baldwin, D.R.; Smith, C.J.P.; Hubbard, R.B. Using socio-demographic and early clinical features in general practice to identify people with lung cancer earlier. Thorax 2013, 68, 451-459.
13. Maisonneuve, P.; Bagnardi, V.; Bellomi, M.; Spaggiari, L.; Pelosi, G.; Rampinelli, C.; Bertolotti, R.; Rotmensz, N.; Field, J.K.; Decensi, A. et al. Lung cancer risk prediction to select smokers for screening CT-A model based on the Italian COSMOS trial. Cancer Prev. Res. (Phila) 2011, 4, 1778-1789.
14. Thun, M.J.; Henley, S.J.; Calle, E.E. Tobacco use and cancer: An epidemiologic perspective for geneticists. Oncogene 2002, 21, 7307-7325.
15. Cooper, D.N. The Molecular Genetics of Lung Cancer; Springer: Heidelberg, Germany, 2005.
16. Zienolddiny, S.; Campa, D.; Lind, H.; Ryberg, D.; Skaug, V.; Stangeland, L.; Phillips, D.H.; Canzian, F.; Haugen, A. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 2006, 27, 560-567.
17. Young, R.P.; Hopkins, R.J.; Hay, B.A.; Epton, M.J.; Mills, G.D.; Black, P.N.; Gardner, H.D.; Sullivan, R.; Gamble, G.D. Lung cancer susceptibility model based on age, family history and genetic variants. PLoS One 2009, 4, e5302.
18. Spitz, M.R.; Etzel, C.J.; Dong, Q.; Amos, C.I.; Wei, Q.; Wu, X.; Hong, W.K. An expanded risk prediction model for lung cancer. Cancer Prev. Res. (Phila) 2008, 1, 250-254.
19. Patz, E.F., Jr.; Goodman, P.C.; Bepler, G. Screening for lung cancer. N. Engl. J. Med. 2000, 343, 1627-1633.
20. Brett, G.Z. Earlier diagnosis and survival in lung cancer. Br. Med. J. 1969, 4, 260-262.
21. Oken, M.M.; Hocking, W.G.; Kvale, P.A.; Andriole, G.L.; Buys, S.S.; Church, T.R.; Crawford, E.D.; Fouad, M.N.; Isaacs, C.; Reding, D.J. et al. Screening by chest radiograph and lung cancer mortality: The Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 2011, 306, 1865-1873.
22. Marcus, P.M.; Bergstralh, E.J.; Fagerstrom, R.M.; Williams, D.E.; Fontana, R.; Taylor, W.F.; Prorok, P.C. Lung cancer mortality in the Mayo Lung Project: Impact of extended follow-up. J. Natl. Cancer Inst. 2000, 92, 1308-1316.
23. Jett, J.R.; Midthun, D.E. Screening for lung cancer: Current status and future directions: Thomas A. Neff lecture. Chest 2004, 125, 158S-162S.
24. Manser, R.; Lethaby, A.; Irving, L.B.; Stone, C.; Byrnes, G.; Abramson, M.J.; Campbell, D. Screening for lung cancer. Cochrane Database Syst. Rev. 2013, 6, doi:10.1002/14651858.CD001991.pub2.
25. Aberle, D.R.; Adams, A.M.; Berg, C.D.; Black, W.C.; Clapp, J.D.; Fagerstrom, R.M.; Gareen, I.F.; Gatsonis, C.; Marcus, P.M. et al. Trial research team reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 2011, 365, 395-409.
26. Moyer, V.A. Screening for Lung Cancer: U.S. preventive services task force recommendation statement. Ann. Intern. Med. 2013, 160, 330-338.
27. Van Iersel, C.A.; de Koning, H.J.; Draisma, G.; Mali, W.P.T.M.; Scholten, E.T.; Nackaerts, K.; Prokop, M.; Habbema, J.D.F.; Oudkerk, M.; van Klaveren, R.J. Risk-based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int. J. Cancer 2007, 120, 868-874.
28. Heuvelmans, M.A.; Oudkerk, M.; de Bock, G.H.; de Koning, H.J.; Xie, X.; van Ooijen, P.M.A.; Greuter, M.J.W.; de Jong, P.A.; Groen, H.J.M.; Vliegenthart, R. Optimisation of volume-doubling time cutoff for fast-growing lung nodules in CT lung cancer screening reduces false-positive referrals. Eur. Radiol. 2013, 23, 1836-1845.
29. Saghir, Z.; Dirksen, A.; Ashraf, H.; Bach, K.S.; Brodersen, J.; Clementsen, P.F.; Døssing, M.; Hansen, H.; Kofoed, K.F.; Larsen, K.R. et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: Status after five annual screening rounds with low-dose CT. Thorax 2012, 67, 296-301.
30. Nackaerts, K.; Vansteenkiste, J. Low-dose CT screening for lung cancer: Trial and error? J. Thorac. Oncol. 2009, 4, 563-564.
31. Van den Bergh, K.A.M.; Essink-Bot, M.-L.; Bunge, E.M.; Scholten, E.T.; Prokop, M.; van Iersel, C.A.; van Klaveren, R.J.; de Koning, H.J. Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial). Cancer 2008, 113, 396-404.
32. Van den Bergh, K.A.M.; Essink-Bot, M.L.; Borsboom, G.J.J.M.; Scholten, E.T.; van Klaveren, R.J.; de Koning, H.J. Long-term effects of lung cancer computed tomography screening on health-related quality of life: The NELSON trial. Eur. Respir. J. 2011, 38, 154-161.
33. Braithwaite, D.; Zhu, W.; Hubbard, R.A.; O'Meara, E.S.; Miglioretti, D.L.; Geller, B.; Dittus, K.; Moore, D.; Wernli, K.J.; Mandelblatt, J. et al. Screening outcomes in older US women undergoing multiple mammograms in community practice: Does interval, age, or comorbidity score affect tumor characteristics or false positive rates? J. Natl. Cancer Inst. 2013, 105, 334-341.
34. Kovalchik, S.A.; Tammemagi, M.; Berg, C.D.; Caporaso, N.E.; Riley, T.L.; Korch, M.; Silvestri, G.A.; Chaturvedi, A.K.; Katki, H.A. Targeting of low-dose CT screening according to the risk of lung-cancer death. N. Engl. J. Med. 2013, 369, 245-254.
35. Mettler, F.A., Jr.; Huda, W.; Yoshizumi, T.T.; Mahesh, M. Effective doses in radiology and diagnostic nuclear medicine: A catalog. Radiology 2008, 248, 254-263.
36. Bach, P.B.; Mirkin, J.N.; Oliver, T.K.; Azzoli, C.G.; Berry, D.A.; Brawley, O.W.; Byers, T.; Colditz, G.A.; Gould, M.K.; Jett, J.R. et al. Benefits and harms of CT screening for lung cancer: A systematic review. JAMA 2012, 307, 2418-2429.
37. Tokarskaya, Z.B.; Scott, B.R.; Zhuntova, G.V.; Okladnikova, N.D.; Belyaeva, Z.D.; Khokhryakov, V.F.; Schöllnberger, H.; Vasilenko, E.K. Interaction of radiation and smoking in lung cancer induction among workers at the Mayak nuclear enterprise. Health Phys. 2002, 83, 833-846.
38. Silvestri, G.A. Screening for lung cancer: It works, but does it really work? Ann. Intern. Med. 2011, 155, 537-539.
39. Patz, E.F., Jr.; Pinsky, P.; Gatsonis, C.; Sicks, J.D.; Kramer, B.S.; Tammemägi, M.C.; Chiles, C.; Black, W.C.; Aberle, D.R. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern. Med. 2013, 174, 269-274.
40. Yu, L.; Todd, N.W.; Xing, L.; Xie, Y.; Zhang, H.; Liu, Z.; Fang, H.; Zhang, J.; Katz, R.L.; Jiang, F. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int. J. Cancer 2010, 127, 2870-2878.
41. Franklin, W.A.; Gazdar, A.F.; Haney, J.; Wistuba, I.I.; LaRosa, F.G.; Kennedy, T.; Ritchey, D.M.; Miller, Y.E. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J. Clin. Investig. 1997, 100, 2133-2137.
42. Wistuba, I.I.; Lam, S.; Behrens, C.; Virmani, A.K.; Fong, K.M.; LeRiche, J.; Samet, J.M.; Srivastava, S.; Minna, J.D.; Gazdar, A.F. Molcular damage in the bronchial epithelium of current and former smokers. J. Natl. Cancer Inst. 1997, 89, 1366-1373.
43. Mao, L.; Lee, J.S.; Kurie, J.M.; Fan, Y.H.; Lippman, S.M.; Lee, J.J.; Ro, J.Y.; Broxson, A.; Yu, R.; Morice, R.C. et al. Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst. 1997, 89, 857-862.
44. Tang, X.; Shigematsu, H.; Bekele, B.N.; Roth, J.A.; Minna, J.D.; Hong, W.K.; Gazdar, A.F.; Wistuba, I.I. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 2005, 65, 7568-7572.
45. Powell, C.A.; Klares, S.; O'Connor, G.; Brody, J.S. Loss of heterozygosity in epithelial cells obtained by bronchial brushing: Clinical utility in lung cancer. Clin. Cancer Res. 1999, 5, 2025-2034.
46. Spira, A.; Beane, J.E.; Shah, V.; Steiling, K.; Liu, G.; Schembri, F.; Gilman, S.; Dumas, Y.-M.; Calner, P.; Sebastiani, P. et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat. Med. 2007, 13, 361-366.
47. Beane, J.; Sebastiani, P.; Whitfield, T.H.; Steiling, K.; Dumas, Y.-M.; Lenburg, M.E.; Spira, A. A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev. Res. (Phila) 2008, 1, 56-64.
48. Li, Q.K.; Shah, P.; Li, Y.; Aiyetan, P.O.; Chen, J.; Yung, R.; Molena, D.; Gabrielson, E.; Askin, F.; Chan, D.W. et al. Glycoproteomic analysis of bronchoalveolar lavage (BAL) fluid identifies tumor-associated glycoproteins from lung adenocarcinoma. J. Proteome Res. 2013, 12, 3689-3696.
49. Hassanein, M.; Callison, J.C.; Callaway-Lane, C.; Aldrich, M.C.; Grogan, E.L.; Massion, P.P. The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev. Res. (Phila) 2012, 5, 992-1006.
50. Spira, A.; Beane, J.; Shah, V.; Liu, G.; Schembri, F.; Yang, X.; Palma, J.; Brody, J.S. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc. Natl. Acad. Sci. USA 2004, 101, 10143-10148.
51. Steiling, K.; Kadar, A.Y.; Bergerat, A.; Flanigon, J.; Sridhar, S.; Shah, V.; Ahman, R.Q.; Brody, J.S.; Lenburg, M.E.; Steffen, M. et al. Comparison of proteomic and transcriptomic profiles in the bronchial airway of current and never smokers. PLoS One 2009, 4, e5043.
52. Sridhar, S.; Schembri, F.; Zeskind, J.; Shah, V.; Gustafson, A.M.; Steiling, K.; Liu, G.; Dumas, Y.-M.; Zhang, X.; Brody, J.S. et al. Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. BMC Genomics 2008, 9, doi:10.1186/1471-2164-9-259.
53. Zhang, X.; Sebastiani, P.; Liu, G.; Schembri, F.; Zhang, X.; Dumas, Y.M.; Langer, E.M.; Alekseyev, Y.; O'Connor, G.T.; Brooks, D.R. et al. Similarities and differences between smoking-related gene expression in nasal and bronchial epithelium. Physiol. Genomics 2010, 41, 1-8.
54. Boyle, J.O.; Gümüs, Z.H.; Kacker, A.; Choksi, V.L.; Bocker, J.M.; Zhou, X.K.; Yantiss, R.K.; Hughes, D.B.; Du, B.; Judson, B.L. et al. Effects of cigarette smoke on the human oral mucosal transcriptome. Cancer Prev. Res. (Phila) 2010, 3, 266-278.
55. Flehinger, B.J.; Melamed, M.R.; Zaman, M.B.; Heelan, R.T.; Perchick, W.B.; Martini, N. Early lung cancer detection: Results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering study. Am. Rev. Respir. Dis. 1984, 130, 555-560.
56. Mao, L.; Hruban, R.H.; Boyle, J.O.; Tockman, M.; Sidransky, D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 1994, 54, 1634-1637.
57. Li, R.; Todd, N.W.; Qiu, Q.; Fan, T.; Zhao, R.Y.; Rodgers, W.H.; Fang, H.-B.; Katz, R.L.; Stass, S.A.; Jiang, F. Genetic deletions in sputum as diagnostic markers for early detection of stage I non-small cell lung cancer. Clin. Cancer Res. 2007, 13, 482-487.
58. Belinsky, S.A.; Palmisano, W.A.; Gilliland, F.D.; Crooks, L.A.; Divine, K.K.; Winters, S.A.; Grimes, M.J.; Harms, H.J.; Tellez, C.S.; Smith, T.M. et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 2002, 62, 2370-2377.
59. Palmisano, W.A.; Divine, K.K.; Saccomanno, G.; Gilliland, F.D.; Baylin, S.B.; Herman, J.G.; Belinsky, S.A. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000, 60, 5954-5958.
60. Diamandis, E.P.; Goodglick, L.; Planque, C.; Thornquist, M.D. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin. Cancer Res. 2011, 17, 2395-2399.
61. Ajona, D.; Pajares, M.J.; Corrales, L.; Perez-Gracia, J.L.; Agorreta, J.; Lozano, M.D.; Torre, W.; Massion, P.P.; de-Torres, J.P.; Jantus-Lewintre, E. et al. Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. J. Natl. Cancer Inst. 2013, 105, 1385-1393.
62. Boeri, M.; Verri, C.; Conte, D.; Roz, L.; Modena, P.; Facchinetti, F.; Calabrò, E.; Croce, C.M.; Pastorino, U.; Sozzi, G. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. Natl. Acad. Sci. USA 2011, 108, 3713-3718.
63. Bianchi, F.; Nicassio, F.; Marzi, M.; Belloni, E.; Dall'Olio, V.; Bernard, L.; Pelosi, G.; Maisonneuve, P.; Veronesi, G.; di Fiore, P.P. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol. Med. 2011, 3, 495-503.
64. Bibikova, M.; Lin, Z.; Zhou, L.; Chudin, E.; Garcia, E.W.; Wu, B.; Doucet, D.; Thomas, N.J.; Wang, Y.; Vollmer, E. et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res. 2006, 16, 383-393.
65. Wilson, I.M.; Davies, J.J.; Weber, M.; Brown, C.J.; Alvarez, C.E.; MacAulay, C.; Schübeler, D.; Lam, W.L. Epigenomics: Mapping the methylome. Cell Cycle 2006, 5, 155-158.
66. Ostroff, R.M.; Bigbee, W.L.; Franklin, W.; Gold, L.; Mehan, M.; Miller, Y.E.; Pass, H.I.; Rom, W.N.; Siegfried, J.M.; Stewart, A. et al. Unlocking biomarker discovery: Large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 2010, 5, e15003.
67. Tanaka, F.; Yoneda, K.; Kondo, N.; Hashimoto, M.; Takuwa, T.; Matsumoto, S.; Okumura, Y.; Rahman, S.; Tsubota, N.; Tsujimura, T. et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin. Cancer Res. 2009, 15, 6980-6986.
68. Yildiz, P.B.; Shyr, Y.; Rahman, J.S.M.; Wardwell, N.R.; Zimmerman, L.J.; Shakhtour, B.; Gray, W.H.; Chen, S.; Li, M.; Roder, H. et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J. Thorac. Oncol. 2007, 2, 893-901.
69. Pecot, C.V.; Li, M.; Zhang, X.J.; Rajanbabu, R.; Calitri, C.; Bungum, A.; Jett, J.R.; Putnam, J.B.; Callaway-Lane, C.; Deppen, S. et al. Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. Cancer Epidemiol. Biomark. Prev. 2012, 21, 786-792.
70. Li, X.; Hayward, C.; Fong, P.-Y.; Dominguez, M.; Hunsucker, S.W.; Lee, L.W.; McLean, M.; Law, S.; Butler, H.; Schirm, M. et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci. Transl. Med. 2013, 5, doi:10.1126/scitranslmed.3007013.
71. Shopland, D.R. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ. Health Perspect. 1995, 103, 131-142.
72. King, B.; Dube, S.; Kaufmann, R.; Shaw, L.; Pechacek, T. Vital signs: Current cigarette smoking among adults aged ≥18 Years-United States, 2005-2010. Morb. Mortal. Wkly. Rep. 2011, 60, 1207-1212.
73. Anthonisen, N.R.; Skeans, M.A.; Wise, R.A.; Manfreda, J.; Kanner, R.E.; Connett, J.E. The effects of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trial. Ann. Intern. Med. 2005, 142, 233-239.
74. Villanti, A.C.; Jiang, Y.; Abrams, D.B.; Pyenson, B.S. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PLoS One 2013, 8, e71379.
75. Sporn, M.B. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 1976, 36, 2699-2702.
76. Hirsch, F.R.; Lippman, S.M. Advances in the biology of lung cancer chemoprevention. J. Clin. Oncol. 2005, 23, 3186-3197.
77. Kelloff, G.J.; Lippman, S.M.; Dannenberg, A.J.; Sigman, C.C.; Pearce, H.L.; Reid, B.J.; Szabo, E.; Jordan, V.C.; Spitz, M.R.; Mills, G.B. et al. Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-A plan to move forward. Clin. Cancer Res. 2006, 12, 3661-3697.
78. Khuri, F.R.; Cohen, V. Molecularly targeted approaches to the chemoprevention of lung cancer. Clin. Cancer Res. 2004, 10, 4249s-4253s.
79. Keith, R.L. Chemoprevention of lung cancer. Proc. Am. Thorac. Soc. 2009, 6, 187-193.
80. Greenberg, A.K.; Tsay, J.-C.; Tchou-Wong, K.-M.; Jorgensen, A.; Rom, W.N. Chemoprevention of lung cancer: Prospects and disappointments in human clinical trials. Cancers 2013, 5, 131-148.
81. Keith, R.L.; Miller, Y.E. Lung cancer chemoprevention: Current status and future prospects. Nat. Rev. Clin. Oncol. 2013, 10, 334-343.
82. The α-Tocopherol, β carotene cancer prevention study group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 1994, 330, 1029-1035.
83. Lee, I.M.; Cook, N.R.; Manson, J.E.; Buring, J.E.; Hennekens, C.H. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: The Women's Health Study. J. Natl. Cancer Inst. 1999, 91, 2102-2106.
84. Hennekens, C.H.; Buring, J.E.; Manson, J.E.; Stampfer, M.; Rosner, B.; Cook, N.R.; Belanger, C.; LaMotte, F.; Gaziano, J.M.; Ridker, P.M. et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 1996, 334, 1145-1149.
85. Albanes, D.; Heinonen, O.P.; Taylor, P.R.; Virtamo, J.; Edwards, B.K.; Rautalahti, M.; Hartman, A.M.; Palmgren, J.; Freedman, L.S.; Haapakoski, J. et al. α-Tocopherol and beta-carotene supplements and lung cancer incidence in the α-tocopherol, beta-carotene cancer prevention study: Effects of base-line characteristics and study compliance. J. Natl. Cancer Inst. 1996, 88, 1560-1570.
86. Virtamo, J.; Pietinen, P.; Huttunen, J.K.; Korhonen, P.; Malila, N.; Virtanen, M.J.; Albanes, D.; Taylor, P.R.; Albert, P.; ATBC Study Group. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: A postintervention follow-up. JAMA 2003, 290, 476-485.
87. Omenn, G.S.; Goodman, G.E.; Thornquist, M.D.; Balmes, J.; Cullen, M.R.; Glass, A.; Keogh, J.P.; Meyskens, F.L.; Valanis, B.; Williams, J.H. et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 1996, 334, 1150-1155.
88. Clark, L.C.; Combs, G.F., Jr.; Turnbull, B.W.; Slate, E.H.; Chalker, D.K.; Chow, J.; Davis, L.S.; Glover, R.A.; Graham, G.F. et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996, 276, 1957-1963.
89. Reid, M.E.; Duffield-Lillico, A.J.; Garland, L.; Turnbull, B.W.; Clark, L.C.; Marshall, J.R. Selenium supplementation and lung cancer incidence: An update of the nutritional prevention of cancer trial. Cancer Epidemiol. Biomark. Prev. 2002, 11, 1285-1291.
90. Fleet, J.C. Dietary selenium repletion may reduce cancer incidence in people at high risk who live in areas with low soil selenium. Nutr. Rev. 1997, 55, 277-279.
91. Lipman, S.M.; Klein, E.A.; Goodman, P.J.; Lucia, M.S.; Thompson, I.M.; Ford, L.G.; Parnes, H.L.; Minsian, L.M.; Gaziano, J.M. et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301, 39-51.
92. Xu, J.; Yin, Z.; Gao, W.; Liu, L.; Wang, R.; Huang, P.; Yin, Y.; Liu, P.; Yu, R.; Shu, Y. Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk. Clin. Lung Cancer 2012, 13, 44-51.
93. Slatore, C.G.; Au, D.H.; Littman, A.J.; Satia, J.A.; White, E. Association of nonsteroidal anti-inflammatory drugs with lung cancer: Results from a large cohort study. Cancer Epidemiol. Biomark. Prev. 2009, 18, 1203-1207.
94. Cook, N.R.; Lee, I.-M.; Gaziano, J.M.; Gordon, D.; Ridker, P.M.; Manson, J.E.; Hennekens, C.H.; Buring, J.E. Low-dose aspirin in the primary prevention of cancer: The Women's Health Study: A randomized controlled trial. JAMA 2005, 294, 47-55.
95. Rothwell, P.M.; Fowkes, F.G.R.; Belch, J.F.F.; Ogawa, H.; Warlow, C.P.; Meade, T.W. Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 2011, 377, 31-41.
96. Govindarajan, R.; Ratnasinghe, L.; Simmons, D.L.; Siegel, E.R.; Midathada, M.V.; Kim, L.; Kim, P.J.; Owens, R.J.; Lang, N.P. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J. Clin. Oncol. 2007, 25, 1476-1481.
97. Colmers, I.N.; Bowker, S.L.; Johnson, J.A. Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab. 2012, 38, 475-484.
98. Pioglitazone for Lung Cancer Chemoprevention. Available online: http://clinicaltrials.gov/show/NCT00780234 (accessed on 14 December 2013).
99. Lee, J.S.; Lippman, S.M.; Benner, S.E.; Lee, J.J.; Ro, J.Y.; Lukeman, J.M.; Morice, R.C.; Peters, E.J.; Pang, A.C.; Fritsche, H.A., Jr. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J. Clin. Oncol. 1994, 12, 937-945.
100. Kelly, K.; Kittelson, J.; Franklin, W.A.; Kennedy, T.C.; Klein, C.E.; Keith, R.L.; Dempsey, E.C.; Lewis, M.; Jackson, M.K.; Hirsch, F.R. et al. A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. Cancer Prev. Res. (Phila) 2009, 2, 440-449.
101. Arnold, A.M.; Browman, G.P.; Levine, M.N.; D'Souza, T.; Johnstone, B.; Skingley, P.; Turner-Smith, L.; Cayco, R.; Booker, L.; Newhouse, M. The effect of the synthetic retinoid etretinate on sputum cytology: Results from a randomised trial. Br. J. Cancer 1992, 65, 737-743.
102. Kurie, J.M.; Lee, J.S.; Khuri, F.R.; Mao, L.; Morice, R.C.; Lee, J.J.; Walsh, G.L.; Broxson, A.; Lippman, S.M.; Ro, J.Y. et al. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin. Cancer Res. 2000, 6, 2973-2979.
103. McLarty, J.W.; Holiday, D.B.; Girard, W.M.; Yanagihara, R.H.; Kummet, T.D.; Greenberg, S.D. Beta-Carotene, vitamin A, and lung cancer chemoprevention: Results of an intermediate endpoint study. Am. J. Clin. Nutr. 1995, 62, 1431S-1438S.
104. Lam, S.; MacAulay, C.; le Riche, J.C.; Dyachkova, Y.; Coldman, A.; Guillaud, M.; Hawk, E.; Christen, M.-O.; Gazdar, A.F. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J. Natl. Cancer Inst. 2002, 94, 1001-1009.
105. Mao, J.T.; Fishbein, M.C.; Adams, B.; Roth, M.D.; Goodglick, L.; Hong, L.; Burdick, M.; Strieter, E.R.M.; Holmes, C.; Tashkin, D.P. et al. Celecoxib decreases Ki-67 proliferative index in active smokers. Clin. Cancer Res. 2006, 12, 314-320.
106. Kim, E.S.; Hong, W.K.; Lee, J.J.; Mao, L.; Morice, R.C.; Liu, D.D.; Jimenez, C.A.; Eapen, G.A.; Lotan, R.; Tang, X. et al. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev. Res. (Phila) 2010, 3, 148-159.
107. Keith, R.L.; Blatchford, P.J.; Kittelson, J.; Minna, J.D.; Kelly, K.; Massion, P.P.; Franklin, W.A.; Mao, J.; Wilson, D.O.; Merrick, D.T. et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev. Res. (Phila) 2011, 4, 793-802.
108. Lam, S.; McWilliams, A.; LeRiche, J.; MacAulay, C.; Wattenberg, L.; Szabo, E. A phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol. Biomark. Prev. 2006, 15, 1526-1531.
109. Gustafson, A.M.; Soldi, R.; Anderlind, C.; Scholand, M.B.; Qian, J.; Zhang, X.; Cooper, K.; Walker, D.; McWilliams, A.; Liu, G. et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci. Transl. Med. 2010, 2, doi:10.1126/scitranslmed.3000251.
110. Lippman, S.M.; Lee, J.J.; Karp, D.D.; Vokes, E.E.; Benner, S.E.; Goodman, G.E.; Khuri, F.R.; Marks, R.; Winn, R.J.; Fry, W. et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J. Natl. Cancer Inst. 2001, 93, 605-618.
111. Van Zandwijk, N.; Dalesio, O.; Pastorino, U.; de Vries, N.; van Tinteren, H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J. Natl. Cancer Inst. 2000, 92, 977-986.
112. Karp, D.D.; Lee, S.J.; Keller, S.M.; Wright, G.S.; Aisner, S.; Belinsky, S.A.; Johnson, D.H.; Johnston, M.R.; Goodman, G.; Clamon, G. et al. Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J. Clin. Oncol. 2013, 31, 4179-4187.
113. Wick, M.; Hurteau, G.; Dessev, C.; Chan, D.; Geraci, M.W.; Winn, R.A.; Heasley, L.E.; Nemenoff, R.A. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol. Pharmacol. 2002, 62, 1207-1214.
114. Bren-Mattison, Y.; van Putten, V.; Chan, D.; Winn, R.; Geraci, M.W.; Nemenoff, R.A. Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 2005, 24, 1412-1422.
115. Nemenoff, R.; Meyer, A.M.; Hudish, T.M.; Mozer, A.B.; Snee, A.; Narumiya, S.; Stearman, R.S.; Winn, R.A.; Weiser-Evans, M.; Geraci, M.W. et al. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-Activated receptor gamma. Cancer Prev. Res. (Phila) 2008, 1, 349-356.
116. Lam, S.; leRiche, J.C.; McWilliams, A.; Macaulay, C.; Dyachkova, Y.; Szabo, E.; Mayo, J.; Schellenberg, R.; Coldman, A.; Hawk, E. et al. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin. Cancer Res. 2004, 10, 6502-6511.
117. Veronesi, G.; Szabo, E.; Decensi, A.; Guerrieri-Gonzaga, A.; Bellomi, M.; Radice, D.; Ferretti, S.; Pelosi, G.; Lazzeroni, M.; Serrano, D. et al. Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev. Res. (Phila) 2011, 4, 34-42.
118. Crowell, J.A. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: An overview. Eur. J. Cancer 2005, 41, 1889-1910.
119. Gerhauser, C.; Bartsch, H.; Crowell, J.; de Flora, S.; D'Incalci, M.; Dittrich, C.; Frank, N.; Mihich, E.; Steffen, C.; Tortora, G. et al. Development of novel cancer chemopreventive agents in Europe-neglected Cinderella or rising phoenix? A critical commentary. ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18-20, 2005. Eur. J. Cancer 2006, 42, 1338-1343.
120. Mascaux, C.; Feser, W.J.; Lewis, M.T.; Barón, A.E.; Coldren, C.D.; Merrick, D.T.; Kennedy, T.C.; Eckelberger, J.I.; Rozeboom, L.M.; Franklin, W.A. et al. Endobronchial miRNAs as biomarkers in lung cancer chemoprevention. Cancer Prev. Res. (Phila) 2013, 6, 100-108.